19531695|t|Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
19531695|a|OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for atrial fibrillation. Laboratory test findings on admission were notable only for a flecainide plasma concentration of 1360 microg/L (reference range 200-1000). A metabolic drug interaction between flecainide and paroxetine, which the patient had been taking for more than 5 years, was considered. Paroxetine was discontinued and the dose of flecainide was reduced to 50 mg twice daily. Her delirium resolved 3 days later. DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients. A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium. According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium. Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.
19531695	0	8	Delirium	DiseaseOrPhenotypicFeature	D003693
19531695	14	21	patient	OrganismTaxon	9606
19531695	33	43	flecainide	ChemicalEntity	D005424
19531695	119	129	paroxetine	ChemicalEntity	D017374
19531695	164	174	flecainide	ChemicalEntity	D005424
19531695	183	191	delirium	DiseaseOrPhenotypicFeature	D003693
19531695	248	258	paroxetine	ChemicalEntity	D017374
19531695	357	366	confusion	DiseaseOrPhenotypicFeature	D003221
19531695	371	379	paranoia	DiseaseOrPhenotypicFeature	D010259
19531695	425	432	patient	OrganismTaxon	9606
19531695	444	454	carvedilol	ChemicalEntity	C043211
19531695	474	482	warfarin	ChemicalEntity	D014859
19531695	493	503	folic acid	ChemicalEntity	D005492
19531695	514	527	levothyroxine	ChemicalEntity	D013974
19531695	544	556	pantoprazole	ChemicalEntity	C064276
19531695	568	578	paroxetine	ChemicalEntity	D017374
19531695	594	604	flecainide	ChemicalEntity	D005424
19531695	625	635	Flecainide	ChemicalEntity	D005424
19531695	671	690	atrial fibrillation	DiseaseOrPhenotypicFeature	D001281
19531695	754	764	flecainide	ChemicalEntity	D005424
19531695	868	878	flecainide	ChemicalEntity	D005424
19531695	883	893	paroxetine	ChemicalEntity	D017374
19531695	905	912	patient	OrganismTaxon	9606
19531695	968	978	Paroxetine	ChemicalEntity	D017374
19531695	1012	1022	flecainide	ChemicalEntity	D005424
19531695	1061	1069	delirium	DiseaseOrPhenotypicFeature	D003693
19531695	1105	1115	Flecainide	ChemicalEntity	D005424
19531695	1172	1178	sodium	ChemicalEntity	D012964
19531695	1198	1206	delirium	DiseaseOrPhenotypicFeature	D003693
19531695	1222	1230	patients	OrganismTaxon	9606
19531695	1339	1349	flecainide	ChemicalEntity	D005424
19531695	1353	1359	CYP2D6	GeneOrGeneProduct	1565
19531695	1375	1385	paroxetine	ChemicalEntity	D017374
19531695	1389	1395	CYP2D6	GeneOrGeneProduct	1565
19531695	1436	1446	flecainide	ChemicalEntity	D005424
19531695	1455	1463	delirium	DiseaseOrPhenotypicFeature	D003693
19531695	1509	1519	flecainide	ChemicalEntity	D005424
19531695	1550	1557	patient	OrganismTaxon	9606
19531695	1560	1568	delirium	DiseaseOrPhenotypicFeature	D003693
19531695	1676	1686	flecainide	ChemicalEntity	D005424
19531695	1691	1701	paroxetine	ChemicalEntity	D017374
19531695	1733	1743	flecainide	ChemicalEntity	D005424
19531695	1776	1784	delirium	DiseaseOrPhenotypicFeature	D003693
19531695	1794	1802	toxicity	DiseaseOrPhenotypicFeature	D064420
19531695	1818	1828	flecainide	ChemicalEntity	D005424
19531695	1848	1858	paroxetine	ChemicalEntity	D017374
19531695	1876	1882	CYP2D6	GeneOrGeneProduct	1565
19531695	1895	1905	flecainide	ChemicalEntity	D005424
19531695	1977	1983	CYP2D6	GeneOrGeneProduct	1565
19531695	Association	D012964	D003693	Novel
19531695	Negative_Correlation	D017374	1565	No
19531695	Positive_Correlation	D017374	D003693	Novel
19531695	Association	D005424	1565	No
19531695	Association	D005424	D012964	Novel
19531695	Drug_Interaction	D005424	D017374	Novel
19531695	Positive_Correlation	D005424	D003693	Novel
19531695	Negative_Correlation	D005424	D001281	No